GBS acquires Intelligent Fingerprinting for stock; expands non-invasive drug testing

INTELLIGENT BIO SOLUTIONS INC.

Acquired IFP for 2,963,091 common shares + 2,363,003 Series C preferred; up to 1,649,273 additional preferred reserved.
IFP's 10-min fingerprint sweat test detects opioids, cocaine, methamphetamines, benzodiazepines, marijuana; over 200 customers.
Board increased to 7 members; Jason Isenberg and David Jenkins appointed as directors.
Preferred shares convertible into 3 common shares, subject to shareholder approval; 12-month lock-up on issued shares.
GBS to file TGA application for IFP's CE Mark in Australia; IFP's UK ISO 13485 facility complements GBS Australia facility.

item 1.01 item 2.01 item 2.03 item 3.02 item 3.03 item 5.02 item 5.03 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason Isenberg

Director

INBS · INTELLIGENT BIO SOLUTIONS INC.

Filed: October 11, 2022, 7:59 PM ET

each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.

Appointed

David Jenkins

Director

INBS · INTELLIGENT BIO SOLUTIONS INC.

Filed: October 11, 2022, 7:59 PM ET

each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Isenberg was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..

Action: appointed
Role: Director

Exact text from the filing

each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Jenkins was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..

Action: appointed
Role: Director

Exact text from the filing

each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.

View on SEC.gov

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-028015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.